MedTrace Logo

Xcellerated T CellsTM in Patients With Multiple Myeloma

NCT00078065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-11-11

No results posted yet for this study

Summary

This trial is a phase II, randomized study of patients with multiple myeloma. All patients will receive Xcellerated T Cells, with or without prior fludarabine therapy.

15 patients in each study arm will be followed for 6 months.

Conditions

Interventions

DRUG

Xcellerated T Cells

Sponsors & Collaborators

  • Xcyte Therapies

    lead INDUSTRY

Principal Investigators

  • Mark W Frohlich, MD · Xcyte Therapies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078065 on ClinicalTrials.gov